Women with estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative invasive lobular carcinoma who are treated with endocrine therapy do not derive any additional ...
Researchers at University of California San Diego have identified a previously unrecognized treatment target for ...
ER+/PR+ breast cancer is a subtype of ER positive breast cancer where the tumor cells express both estrogen receptors (ER) and progesterone receptors (PR) on the surface. As the most common type of ...
From 2010 to 2020, breast cancer deaths among women ages 20-49 declined significantly across all breast cancer subtypes and racial/ethnic groups, with marked declines starting after 2016, according to ...
Comparison between extended and standard infusion in patients with chemotherapy-induced febrile neutropenia: A systematic review, meta-analysis and survival analysis. This is an ASCO Meeting Abstract ...
A new study published today in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer Center details a therapeutic vulnerability in patients with an aggressive ...
It's *** lesser known breast cancer that develops in *** patient's milk producing glands, and cases of lobular breast cancer are on the rise in the US. Most people aren't familiar with this subtype, ...
Triple-negative breast cancer (TNBC) remains one of the most aggressive types of breast cancer. Determined by a lack of three markers, estrogen receptors, progesterone receptors, and HER2/neu protein, ...
Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback